Skip Navigation


JAC Advance Access originally published online on May 19, 2009
Journal of Antimicrobial Chemotherapy 2009 64(2):428-429; doi:10.1093/jac/dkp174
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
64/2/428    most recent
dkp174v2
dkp174v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tan, C.-K.
Right arrow Articles by Hsueh, P.-R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tan, C.-K.
Right arrow Articles by Hsueh, P.-R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Research letters

Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis

Che-Kim Tan1, Chih-Cheng Lai2, Chun-Hsing Liao3, Chien-Hong Chou4, Hsiao-Leng Hsu5, Yu-Tsung Huang5,6 and Po-Ren Hsueh5,6,*

1 Department of Intensive Care Medicine, Chi-Mei Medical Center, Tainan, Taiwan 2 Department of Internal Medicine, Yi-Min Hospital, Taipei, Taiwan 3 Department of Internal Medicine, Far Eastern Memorial Hospital, Taipei County, Taiwan 4 Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin, Taiwan 5 Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan 6 Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan

* Corresponding author. Tel: +886-2-23123456, ext. 65355; Fax: +886-2-23224263; E-mail: hsporen@ntu.edu.tw

Keywords: M. tuberculosis , TB , MDR-TB

The first 10% of the full text of this article appears below.

Sir,

The emergence of resistance of Mycobacterium tuberculosis to fluoroquinolones in patients with newly diagnosed infection has been a concern, especially in patients who have prior exposure to fluoroquinolones.1 Furthermore, the usage of fluoroquinolones in community-acquired infection has been reported to delay the diagnosis of tuberculosis (TB).2,3 The development of a new quinolone that retains the antibacterial activity spectrum of classic fluoroquinolones but with a relatively low activity against M. tuberculosis might have a role to play in removing the concern of potentially delaying the diagnosis of TB.

Nemonoxacin (TG-873870) is a non-fluorinated quinolone . . . [Full Text of this Article]


   Funding
 

   Transparency declarations
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
Y.-H. Chen, C.-Y. Liu, J.-J. Lu, C.-H. R. King, and P.-R. Hsueh
In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan
J. Antimicrob. Chemother., December 1, 2009; 64(6): 1226 - 1229.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
H. J. Adam, N. M. Laing, C. R. King, B. Lulashnyk, D. J. Hoban, and G. G. Zhanel
In Vitro Activity of Nemonoxacin, a Novel Nonfluorinated Quinolone, against 2,440 Clinical Isolates
Antimicrob. Agents Chemother., November 1, 2009; 53(11): 4915 - 4920.
[Abstract] [Full Text] [PDF]